Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Retifanlimab |
Indication/Tumor Type | transitional cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | transitional cell carcinoma | predicted - sensitive | Retifanlimab | Phase II | Actionable | In a Phase II trial (POD1UM-203), Zynyz (retifanlimab) treatment was well tolerated and demonstrated antitumor activity in patients with CD274 (PD-L1)-positive (CPS >/= 10%) urothelial carcinoma, resulting in an overall response rate of 37.9% (11/29, 1 complete and 10 partial responses), disease control rate of 55.2%, median progression-free survival of 5.7 months, median duration or response of 11.5 months, and median overall survival of 15.2 months (PMID: 38401247; NCT03679767). | 38401247 |
PubMed Id | Reference Title | Details |
---|---|---|
(38401247) | A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). | Full reference... |